Post-IPO Equity - Aeglea BioTherapeutics
Investment Firm
Overview
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Announced Date
Jun 22, 2023
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
1
No investment info available on this profile
Round Details and Background
Aeglea BioTherapeutics raised $210000000 on 2023-06-22 in Post-IPO Equity
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jun 22, 2023 |  Post-IPO Equity - Aeglea BioTherapeutics | - | 210.0M | |
| Mar 23, 2015 | Series B - Aeglea BioTherapeutics | 11 | - | 44.0M |
| Feb 06, 2014 | Series A - Aeglea BioTherapeutics | 4 | - | 12.0M |
Recent Activity
There is no recent news or activity for this profile.